Eyelea

RBC Capital Markets analyst Adnan Butt is optimistic on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) following lower sales outside the US by competing Novartis AG (NYSE: NVS) drug Lucentis. Lucentis, is a ranibizumab injection for the treatment of wet age-related macular degeneration...